Your web browser is out of date. Update your browser for more security, speed and the best experience on this site.

Update your browser

to the latest version of Edge, Chrome, Firefox or Safari.

Latest News

Amedisys Floats Future Innovation Plans, Details COVID-19 Costs

Published: 08/05/2020

About five months into the COVID-19 crisis, Amedisys Inc. (Nasdaq: AMED) believes that it’s better positioned for the future than it was before COVID-19 landed on U.S. soil. The Patient-Driven Groupings Model (PDGM) and COVID-19 have presented challenges to the Baton Rouge, Louisiana-based company’s home health business, just like almost everyone else’s. But Amedisys bested its Q2 internal modeling and feels like it’s primed to ride the tailwinds that it’s expecting to take hold on the back half of 2020 and after that. Home health admissions and referrals hit a low point the week of April 5,” Amedisys CEO Paul Kusserow said on the company’s Q2 earnings call. Since that time, I am happy to report that we have seen a steady, V-shaped recovery — a sharp bounce back instead of a prolonged trot.”

New Ideas